GlassScriptPhysician profile
Melvin M Vallette
NPI 1083160246
$2,158.00
in general payments reported to CMS, 2019-2025
24 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,096 · 2022: $61.71.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $367.32 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $355.51 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $315.75 | 2021-2022 | |
| Amgen INC. | $188.91 | 2021 | |
| Lilly USA, LLC | $165.71 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $151.58 | 2021 | |
| Astellas Pharma US INC | $86.64 | 2021 | |
| Novo Nordisk INC | $77.71 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $62.28 | 2021 | |
| Xeris Pharmaceuticals, INC. | $48.74 | 2021 | |
| Merck Sharp & Dohme LLC | $40.72 | 2021 | |
| Mylan Specialty L.P. | $38.27 | 2021 | |
| Dexcom, INC. | $35.26 | 2021 | |
| Nabriva Therapeutics, Plc | $30.19 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $27.57 | 2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $27.27 | 2021 | |
| Janssen Pharmaceuticals, INC | $25.44 | 2021 | |
| Supernus Pharmaceuticals, INC. | $21.01 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $18.85 | 2022 | |
| Novartis Pharmaceuticals Corporation | $17.31 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $15.38 | 2021 | |
| Philips North America LLC | $14.03 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.87 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $12.68 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melvin Vallette listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.